Skip to main content
Premium Trial:

Request an Annual Quote

Upstate to Sell Galapagos Adenovirus Products; Could Play in siRNA Market

NEW YORK, May 17 (GenomeWeb News) - Upstate, a wholly owned subsidiary of Serologicals, will market and sell Galapagos' adenovirus products worldwide, excluding Japan, Galapagos said today.

 

In return, Galapagos will receive double-digit royalties on net sales achieved by Upstate.

 

A "hallmark" of the adenovirus technology is the stability of the knock-in and knock-down protein levels, and the suitability for high-throughput assays using human primary cells, Upstate said.

 

These features should allow the adenovirus technology to compete effectively in the global market for siRNA reagents. Galapagos retains rights to continue servicing its existing customers for these products.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.